Publications
Publications
Show Results For
- All HBS Web
(5,037)
- Faculty Publications (1,301)
- March 2015 (Revised January 2024)
- Case
CV Ingenuity (A): How to Evaluate the Commercial Viability of New Health Care Technologies
By: Regina E. Herzlinger and Andrew Otazo
Duke Rohlen (HBS MBA ’01) hoped to win over a prominent venture capital investor for Series B financing of his firm CVI that was creating a drug-eluting balloon (DES) to treat peripheral arterial disease. As a second-mover, Duke felt he was more likely to acquire... View Details
Keywords: CV Ingenuity; CVI; Drug Eluting Balloon; DEB; Drug Eluting Stent; Angioplasty Balloon; FoxHollow; Medical Device; Medical Device Startup; Premarket Approval; PMA; Lutonix; Stellarex; LEVANT; ILLUMENATE; Clinical Trials; Peripheral Arterial Disease; PAD; Healthcare Startups; Covidien; Health Care and Treatment; Health Testing and Trials; Business Startups; Commercialization; Health Industry; Health Industry; United States; Europe
- March 2015 (Revised February 2022)
- Supplement
CV Ingenuity (B): Epilogue
By: Regina E. Herzlinger and Andrew Otazo
Duke Rohlen used a lea-nfunding, iconoclastic strategy for his start up for a drug eluding balloon for peripheral artery disease. His giant competitors were first movers. Did Duke obtain the funding he sought? How did his DEB fare versus that of his competitors?
The... View Details
Keywords: CV Ingenuity; CVI; Drug Eluting Balloon; DEB; Drug Eluting Stent; Angioplasty Balloon; FoxHollow; Medical Device; Medical Device Startup; Premarket Approval; PMA; Lutonix; Stellarex; LEVANT; ILLUMENATE; Clinical Trials; Peripheral Arterial Disease; PAD; Healthcare Startups; Covidien; Health Care and Treatment; Health Testing and Trials; Business Startups; Commercialization; Strategy; Health Industry; Health Industry; United States; Europe
- March 2015
- Teaching Note
CVS Health: Promoting Drug Adherence
Email mking@hbs.edu for a courtesy copy.
This Teaching Note explains the theory of the case and teaching plan for the case: CVS Health: Promoting Drug Adherence (515010). The case finds Helena Foulkes, Executive... View Details
This Teaching Note explains the theory of the case and teaching plan for the case: CVS Health: Promoting Drug Adherence (515010). The case finds Helena Foulkes, Executive... View Details
Keywords: Medication Adherence; Affordable Care Act (ACA); Marketing Strategy; Communication Strategy; Customer Value and Value Chain; Decisions; Health Care and Treatment; Goals and Objectives; Resource Allocation; Marketing Communications; Consumer Behavior; Measurement and Metrics; Service Delivery; Behavior; Motivation and Incentives; Social Issues; Information Technology; Value Creation; Health Industry; Health Industry; Health Industry; Health Industry; Health Industry; United States
- March 2015
- Case
Twine Health
By: Robert S. Huckman, Ariel D. Stern and Matthew G. Preble
In late 2014, Dr. John Moore (CEO), Frank Moss (chairman), and Scott Gilroy (CTO) of Twine Health (Twine) had to resolve several challenges that threatened to restrict the widespread dissemination of its sole product, Twine. Twine was a cloud-based platform that... View Details
- March 2015
- Case
Bloodbuy
By: Richard G. Hamermesh and Michael Norris
In 2015, Chris Godfrey, founder and CEO of Bloodbuy, has to consider the best path to growth for his young company, which is attempting to disrupt the blood donation industry. View Details
- March 2015
- Case
Transforming Care at UnityPoint Health – Fort Dodge
By: Amy C. Edmondson, Ashley-Kay Fryer and Morten T. Hansen
This case details the transformation of a health care delivery system, UnityPoint Health – Fort Dodge, into a Pioneer Accountable Care Organization (ACO) after the passage of health reform in the United States. The case explores in detail how the hospital CEO and staff... View Details
- March 2015 (Revised June 2015)
- Case
Medalogix
By: Richard G. Hamermesh and Matthew G. Preble
This case examines an exciting new approach to health care that will help care providers identify when hospice services are the appropriate type of care for patients. The company, Medalogix, already has a product on the market that uses a proprietary algorithm to... View Details
Keywords: Health Care; Health Care Entrepreneurship; Health Care Services; Implementing Strategy; Dissemination; Innovation; Market Selection; Health; Health Care and Treatment; Analytics and Data Science; Marketing Strategy; Innovation and Management; Innovation Strategy; Health Industry; United States
- Article
Market-Based Solutions to Antitrust Threats—The Rejection of the Partners Settlement
By: Regina E. Herzlinger, Barak D. Richman and Kevin A. Schulman
- March 2015 (Revised September 2016)
- Case
Terrapin Laboratory
By: Richard G. Hamermesh and Joseph B. Fuller
Describes the formation and rapid growth of a drug testing company. The company needs to decide whether to enter the painkiller testing market, in addition to growing its drug treatment center business. The associated teaching materials provide students the opportunity... View Details
- February 2015 (Revised June 2017)
- Case
Intrapreneurship at DaVita HealthCare Partners
By: Joseph B. Fuller, David J. Collis and Matthew G. Preble
Josh Golomb, president and general manager of DaVita Rx (Rx), was about to meet with Kent Thiry, CEO of Rx's corporate parent, DaVita Healthcare Partners Inc. (DaVita), in August 2013. The two would discuss whether Golomb should lead a new DaVita venture, Paladina... View Details
- February 2015 (Revised November 2015)
- Supplement
Building an Integrated Biopharma Company: Crucell (B)
By: Richard G. Hamermesh, Marianne Van Der Steen and Susan Harmeling
The Crucell (B) case updates events at Crucell since 2009. In September, 2009, Johnson & Johnson acquired 18% of Crucell for $400 million. This investment was part of a business development deal. Subsequently, in 2012, Johnson & Johnson acquired Crucell for $2.8... View Details
Keywords: Biotechnology; Biopharmacy Company; Licensing Agreements In Biopharmacy; Licensing; Human Cell-line Technology; Vaccine; Healthcare Innovation; Global Health; Entrepreneurship; Health Care and Treatment; Acquisition; Innovation and Invention; Biotechnology Industry; Pharmaceutical Industry
- February 2015
- Supplement
The Affordable Care Act (A): Legislative Strategy in the House of Representatives
By: Joseph L. Bower and Michael Norris
In early 2009, the Obama administration and the Democratically-led Congress began working on what would eventually become the Affordable Care Act. The (A) case in this series discusses the legislative strategy in the House of Representatives, where three different... View Details
- February 2015
- Supplement
The Affordable Care Act (C): Legislative Strategy in the Senate
By: Joseph L. Bower and Michael Norris
In 2009, the Senate begins drafting its health care bills. Jurisdiction in the Senate is shared between two committees, but the more important is the Senate Finance Committee. View Details
- February 2015
- Supplement
The Affordable Care Act (D): Making a Decision on the Employer-Sponsored Health Insurance Tax Exclusion
By: Joseph L. Bower and Michael Norris
In the summer of 2009, a meeting is called in the White House to discuss the impact of changing the rules on the employer-sponsored health insurance tax exclusion. View Details
- February 2015
- Supplement
The Affordable Care Act (E): The August 2009 Recess
By: Joseph L. Bower and Michael Norris
During the Congress's August recess in 2009, the Tea Party makes a big push to stop the health reform bill moving through Congress. View Details
- February 2015
- Supplement
The Affordable Care Act (F): Regaining Momentum
By: Joseph L. Bower and Michael Norris
In the fall of 2009, President Obama makes a speech to a joint session of Congress in an attempt to regain lost momentum on health reform and get a bill through Congress. View Details
- February 2015
- Supplement
The Affordable Care Act (G): The Final Votes
By: Joseph L. Bower and Michael Norris
In the fall of 2009, the House and Senate each voted to pass health reform bills. These bills then had to be combined into the Affordable Care Act and the ACA had to be passed by both houses. Reconciliation had to be used because of Republican Scott Brown's Senate... View Details
- February 2015
- Supplement
The Affordable Care Act (H): Implementation Begins
By: Joseph L. Bower and Michael Norris
In the spring of 2010, after the ACA is signed into law, the government begins implementation. View Details
- February 2015
- Supplement
The Affordable Care Act (I): The Supreme Court
By: Joseph L. Bower and Michael Norris
In the spring of 2012, the Supreme Court hears arguments and releases its decision on the constitutionality of the ACA. View Details
- February 2015
- Supplement
The Affordable Care Act (J): Healthcare.gov
By: Joseph L. Bower and Michael Norris
In the fall of 2013, Healthcare.gov launches as an insurance exchange for consumers to buy health insurance. The launch is filled with glitches, and some worry if it will imperil the fate of the entire ACA. View Details